Open AccessDosing vancomycin in the super obese: less is more
Author(s) -
Ryan L. Crass,
Ryan D Dunn,
Joseph Hong,
Lynne C. Krop,
Manjunath P. Pai
Publication year - 2018
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dky310
Subject(s) - dosing , vancomycin , medicine , intensive care medicine , pharmacology , biology , staphylococcus aureus , bacteria , genetics
Vancomycin remains the mainstay of empirical therapy directed against MRSA. National guidelines recommend empirical dosing based on total body weight with trough-level therapeutic drug monitoring (TDM), which may not be optimal in obese and super obese patients. Furthermore, nomograms for empirical vancomycin dosing by estimated kidney function pre-date standardization of creatinine assays.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom